BCM
MACK

BlueCrest Capital Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

BlueCrest Capital Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-27,269
Closed -$114K – 1733
2018
Q3 		$114K Buy
27,269
+972
+4% +$4.1K ﹤0.01% 1375
2018
Q2 		$102K Buy
+26,297
New +$175K ﹤0.01% 1391
2017
Q3 		– Sell
-3,305
Closed -$32K – 1238
2017
Q2 		$32K Buy
+3,305
New +$67.5K ﹤0.01% 874

Other funds holding MACK

NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
2L
22NW LP Seattle, Washington $146M AUM 29.83% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
SC
Sepio Capital Salt Lake City, Utah $1.84B AUM 18.57% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
WIM
Wittenberg Investment Management Carlisle, Massachusetts $269M AUM 28.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlueCrest Capital Management's MACK Position: Q4 2018 in Review

BlueCrest Capital Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q4 2018, closing a stake of 27,269 shares — an estimated $114K sold.

BlueCrest Capital Management first reported a position in MACK in Q2 2017 and held it in 3 quarters. The position peaked at $114K in Q3 2018. 56 funds tracked by Wall St. Rank hold MACK as of Q4 2018.

  • BlueCrest Capital Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
  • BlueCrest Capital Management sold 27,269 Merrimack Pharmaceuticals, Inc. shares in Q4 2018, an estimated $114K.
  • BlueCrest Capital Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q2 2017 and held it in 3 quarters.
  • BlueCrest Capital Management's Merrimack Pharmaceuticals, Inc. position peaked at $114K in Q3 2018.
  • 56 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q4 2018.

Based on BlueCrest Capital Management's 13F filing for Q4 2018, filed 14 Feb 2019.